US Oncology Research Affiliated Investigators Participated in Studies that ... MarketWatch (press release) "When we presented our data with the Syk inhibitor fostamatinib at the ASH plenary session in 2008, B Cell Receptor signaling inhibitors were heralded as a breakthrough on par with the original use of chlorambucil, adriamycin, and rituximab," said Dr. ... |
